Reasoning the effect of immunotherapy after chemoradiation in the PACIFIC trial-Reference-Cited by-同舟云学术

Reasoning the effect of immunotherapy after chemoradiation in the PACIFIC trial

Published:2019-01 Issue:1 Volume:15 Page:81-94
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncology

Author:

Bulbul Ajaz¹²,Araujo-Mino Emilio¹³

Affiliation:

1. Division of Internal Medicine, Department of Hematology/Oncology, Texas Tech University Health Sciences Center School of Medicine, Lubbock, TX 79409, USA

2. Hematology & Oncology, Kymera Independent Physicians, Roswell, Carlsbad, Hobbs, NM 88220, USA

3. Division of Internal Medicine, Department of Hematology/Oncology, University of New Mexico, Albuquerque, NM 87131, USA

Abstract

Durvalumab consolidation after chemoradiation has been a giant leap in the treatment of stage III non-small-cell lung cancer with an unprecedented 16.8-month median progression-free survival. PACIFIC trial is a new foray into chemoimmunotherapy trials where we apply our knowledge of ‘immunogenic cell death’ and ‘Abscopal’ effect of radiation in the clinic. Our understanding of immunotherapy after chemoradiation treatment and application of immunogenic cell death biomarkers in future trials may be the approach we need to maximize benefit of these treatments in the appropriate patients.

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fon-2018-0464

Reference82 articles.

1. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer

2. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial

3. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study

4. Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

5. Gadgeel SM, Stevenson J, Langer CJ Pembrolizumab (pembro) plus chemotherapy as front-line therapy for advanced NSCLC: KEYNOTE-021 cohorts A-C. 34(Suppl. 15), doi:10.1200/JCO.2016.34.15_suppl.9016 (2017).

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The abscopal effect: a sense of DNA damage is in the air;Journal of Clinical Investigation;2021-05-03

2. Diverse Neoantigens and the Development of Cancer Therapies;Seminars in Radiation Oncology;2020-04